Deutsche Bank AG lifted its holdings in Akorn, Inc. (NASDAQ:AKRX) by 8.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,037,471 shares of the company’s stock after purchasing an additional 163,367 shares during the period. Deutsche Bank AG owned about 1.63% of Akorn worth $65,666,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also made changes to their positions in the company. State of Alaska Department of Revenue acquired a new position in shares of Akorn in the 4th quarter worth approximately $199,000. LMR Partners LLP purchased a new position in shares of Akorn in the third quarter worth approximately $200,000. Opera Trading Capital purchased a new position in shares of Akorn in the fourth quarter worth approximately $274,000. ING Groep NV purchased a new position in shares of Akorn in the fourth quarter worth approximately $275,000. Finally, MANA Advisors LLC purchased a new position in shares of Akorn in the fourth quarter worth approximately $332,000. 77.52% of the stock is currently owned by institutional investors.
In related news, major shareholder John N. Kapoor sold 13,629 shares of the business’s stock in a transaction that occurred on Thursday, January 25th. The shares were sold at an average price of $32.67, for a total transaction of $445,259.43. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 28.20% of the company’s stock.
Akorn, Inc. (AKRX) opened at $18.96 on Wednesday. Akorn, Inc. has a 1 year low of $16.79 and a 1 year high of $34.00. The firm has a market cap of $2,376.15, a P/E ratio of 11.78, a PEG ratio of 0.71 and a beta of 1.78. The company has a quick ratio of 3.19, a current ratio of 4.27 and a debt-to-equity ratio of 0.98.
Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.
Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.